Hot Investor Mandate 2: Chinese Pharma Seeks Small Molecules and Biologics from North America and Europe

9 Jun

A pharmaceutical company headquartered in Beijing, China has five subsidiaries that focus on different therapeutic areas. The company is interested in collaborations with biotechnology companies through a variety of collaboration structures including co-development, in/out-licensing, co-promotion, M&A, and joint venture. The company highly prefers products from mature markets like Western Europe and North America.

The firm is currently seeking therapeutic opportunities in Oncology and immunotherapy, Respiratory Diseases, Cardiovascular, CNS, Gastrointestinal, and metabolic disease. For small molecule drugs, the company is interested in in-licensing and co-development of assets in phase 2 trials. Earlier assets may be considered but would require closer scrutiny. For biologics, the company is interested in forming joint ventures.

The firm is looking to partner with companies that seek to enter the Chinese market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: